目的 探讨槐杞黄颗粒联合布地奈德福莫特罗粉吸入剂治疗儿童咳嗽变异性哮喘的临床疗效。方法 选取2013年3月-2016年6月青海省人民医院收治的咳嗽变异性哮喘患儿450例进行研究，按随机数字表法将患儿分为布地奈德福莫特罗组、槐杞黄颗粒组和联合治疗组，每组各150例。布地奈德福莫特罗组吸入布地奈德福莫特罗粉吸入剂，1吸/次，2次/d。槐杞黄颗粒组口服槐杞黄颗粒，2~3岁：5 g/次，4~12岁：10 g/次，2次/d。联合治疗组给予布地奈德福莫特罗粉吸入剂和槐杞黄颗粒，方法同上。各组患儿均连续治疗3个月。观察3组的临床疗效，比较3组的肺功能，炎症反应和免疫功能。结果 治疗后，布地奈德福莫特罗组、杞黄颗粒组和联合治疗组的总有效率分别为78.00%、65.33%、92.00%，联合治疗组总有效率与其他两组比较差异具有统计学意义（P<0.05）。治疗后，3组FEV1%和PEF%均明显上升，同组治疗前后比较差异有统计学意义（P<0.05）；且联合治疗组这些观察指标明显高于布地奈德福莫特罗组和槐杞黄颗粒组，差异具有统计学意义（P<0.05）。治疗后，3组hs-CRP、TNF-α和IL-6水平显著下降，IL-10水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且联合治疗组这些观察指标的改善程度明显优于布地奈德福莫特罗组和槐杞黄颗粒组，差异具有统计学意义（P<0.05）。治疗后，3组IgE、CD⁴⁺、CD⁴⁺/CD⁸⁺明显降低，CD⁸⁺明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且联合治疗组这些观察指标的改善程度明显优于布地奈德福莫特罗组和槐杞黄颗粒组，差异具有统计学意义（P<0.05）。结论 槐杞黄颗粒联合布地奈德福莫特罗粉吸入剂治疗儿童咳嗽变异性哮喘具有较好的临床疗效，能改善肺功能，调节免疫功能和炎症反应，具有一定的临床推广应用价值。

Objective To investigate the effects of Huaiqihuang Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of cough variant asthma in children. Methods Children (450 cases) with cough variant asthma in Qinghai Provincial People's Hospital from March 2013 to June 2016 were randomly divided into budesonide and formoterol, Huaiqihuang Granules and combined therapy groups, and each group had 150 cases. Children in the budesonide and formoterol group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, 1 suction/time, twice daily. Children in the Huaiqihuang Granules group were po administered with Huaiqihuang Granules, 2-3 ages:5 g/time, 4-12 ages:10 g/time, twice daily. Children in the combined therapy group were given Budesonide and Formoterol Fumarate Powder for inhalation and Huaiqihuang Granules as above. Children in three groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and lung function, inflammatory response, and immune function in three groups were compared. Results After treatment, the clinical efficacies in the budesonide and formoterol, Huaiqihuang Granules, and combined therapy groups were 78.00%, 65.33% and 92.00%, respectively, and there was difference among three groups (P<0.05). After treatment, FEV1% and PEF% in three groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the combined therapy group were significantly higher than those in the budesonide and formoterol and Huaiqihuang Granules groups, with significant difference among three groups (P<0.05). After treatment, the levels of hs-CRP, TNF-α, and IL-6 in three groups were significantly decreased, but the levels of IL-10 in three groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the combined therapy group were significantly better than those in the budesonide and formoterol and Huaiqihuang Granules groups, with significant difference among three groups (P<0.05). After treatment, IgE, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in three groups were significantly decreased, but the CD⁸⁺ in three groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the combined therapy group were significantly better than those in the budesonide and formoterol and Huaiqihuang Granules groups, with significant difference among three groups (P<0.05). Conclusion Huaiqihuang Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical curative effect in treatment of cough variant asthma in children, can improve lung function, regulate immune function and inflammatory reaction, which has a certain clinical application value.